Atara Biotherapeutics Inc
NASDAQ:ATRA
Atara Biotherapeutics Inc
NASDAQ:ATRA
Price:
0.6036 USD
Market Closed
Updated:
May 17, 2024
Atara Biotherapeutics Inc
Accrued Liabilities
|
Atara Biotherapeutics Inc
Accrued Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
Accrued Liabilities
$53.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$2.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
34%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
28%
|
See Also
What is Atara Biotherapeutics Inc's Accrued Liabilities?
Accrued Liabilities
53.7m
USD
53.7m
USD
Based on the financial report for Mar 31, 2024, Atara Biotherapeutics Inc's Accrued Liabilities amounts to 53.7m USD.
What is Atara Biotherapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
30%
30%
Over the last year, the Accrued Liabilities growth was 3%. The average annual Accrued Liabilities growth rates for Atara Biotherapeutics Inc have been 32% over the past three years , 30% over the past five years .
You don't have any saved screeners yet
